Today: 20 March 2026
Subscribe
Browse Category

LSE:GSK 30 July 2025 - 5 December 2025

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK shares traded near multi-year highs on 4 December, closing at 1,826–1,837p in London and $48.57 in New York, up over 40% year-to-date. The company repurchased more than 11.5 million shares since late September as part of a £2 billion buyback. New executive share options were granted on 5 December. Market cap stands at about £73 billion in London and just under $100 billion in New York.
5 December 2025
··
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK closed near 1,783p in London on 2 December 2025, just below its 52-week high, after strong Q2 and Q3 results lifted shares nearly 40% over 12 months. Q3 sales rose 8% at constant exchange to £8.5 billion, with oncology up 39% and core EPS up 14%. The ADR ended at $47.19 in New York. Analyst focus remains on the company’s growth pipeline and 2031 revenue targets.
2 December 2025
····
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

GSK shares closed up 0.23% at 1,776p in London on Thursday, trading between 1,772p and 1,790p on light volume. Jefferies raised its target price to 2,100p and reiterated a “Buy” rating. Recent R&D announcements and a new oncology collaboration with LTZ Therapeutics continued to influence sentiment. Over the past year, GSK shares have gained about 36%.
20 November 2025
··
European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

The Stoxx 600 rose 0.18% to 555.53 on Sept. 29, with Germany’s DAX and the FTSE 100 also edging higher, while Italy’s FTSE MIB and Spain’s IBEX 35 slipped 0.22%. Euro-area economic confidence beat forecasts, and German import prices fell 1.5% year-on-year. Healthcare, luxury, and mining stocks gained; banks and energy lagged. GSK jumped on CEO news, while Carnival dropped 4.5% despite raising profit forecasts.
30 September 2025
······
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European stocks closed higher Monday, with the FTSE 100 up 0.5% and the STOXX 600 gaining 0.2% as healthcare and tech outperformed. GSK surged 3.3% after CEO Emma Walmsley’s exit was announced; AstraZeneca rose 1.3% on plans for a New York listing. Lufthansa said it will cut 4,000 jobs. Oil fell 0.6% on resumed Iraqi Kurdish exports and OPEC+ supply news; gold hit a record $3,812 an ounce.
29 September 2025
·······
Wall Street Braces for Shutdown: Stocks Rally as Fed Cuts Loom – Tech & Defense in Focus

Wall Street Braces for Shutdown: Stocks Rally as Fed Cuts Loom – Tech & Defense in Focus

S&P 500 futures rose 0.3% Monday as Congress faced a Tuesday midnight deadline to avert a U.S. government shutdown. Gold hit a record $3,808/oz, while oil slipped near $70 on OPEC+ news. AstraZeneca shares gained 1.3% on its NYSE listing plan; First Brands Group filed for Chapter 11. Investors trimmed Fed rate-cut bets amid mixed economic data and looming jobs report.
29 September 2025
·······
Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging

Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging

Altos Labs, a $3 billion biotech startup backed by Jeff Bezos, published a 2024 study showing partial cellular reprogramming extended lifespan and improved health in mice. The company, led by Hal Barron and Nobel laureate Shinya Yamanaka, focuses on rejuvenating cells to extend healthy years, not immortality. Altos faces competition from firms like Calico and Retro Biosciences in the fast-growing longevity sector.
20 September 2025
··
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

The FDA approved Leqembi IQLIK, the first at-home injectable Alzheimer’s treatment, enabling weekly self-administered doses. U.S. regulators also cleared Sanofi’s Wayrilz, the first BTK inhibitor for chronic immune thrombocytopenia. Cytokinetics’ aficamten outperformed metoprolol in a Phase 3 heart drug trial. WHO warned Gaza has run out of critical medical supplies amid a spike in Guillain-Barré syndrome cases.
30 August 2025
····
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

The U.S. administration fired CDC Director Dr. Susan Monarez after she resisted Health Secretary Robert F. Kennedy Jr.’s directives; four senior CDC officials resigned in protest, citing risks to young Americans and pregnant women. U.S. regulators approved updated COVID-19 vaccines for fall, but limited routine access to adults 65+ and high-risk groups, excluding healthy under-65s.
28 August 2025
····
Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Novartis said two Phase III trials of ianalumab met primary endpoints in Sjögren’s disease, showing significant disease activity reduction. Boehringer Ingelheim’s zongertinib won accelerated FDA approval for HER2-mutant NSCLC. GSK’s gepotidacin received FDA Priority Review for uncomplicated gonorrhea. The U.S. Postal Service began blocking shipments of illicit vaping products amid regulatory scrutiny.
11 August 2025
····
From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

Samsung unveiled the Galaxy Z Fold7 at $1,999 and the Flip7 FE at $899, with the Fold7 26% thinner and 10% lighter than last year’s model. Opera filed an antitrust complaint in Brazil against Microsoft over Edge’s default status. Sony sued Tencent, alleging Light of Motiram copied Horizon Zero Dawn. Figma raised its IPO price range, targeting an $18.8 billion valuation.
30 July 2025
·············
1 2 3 4

Stock Market Today

  • Friday Market Movers: Super Micro Legal Issues, Metals Slump, Big Oil Gains, Housing Stocks Drop
    March 19, 2026, 8:50 PM EDT. Super Micro Computer faces legal charges linked to unauthorized tech exports to China, dropping shares below $30 from $110. Gold, silver, and copper futures have fallen sharply since the Iran war began. In contrast, Big Oil stocks, including Chevron, ExxonMobil, and ConocoPhillips, are climbing amid rising crude prices, with energy the sole S&P 500 sector gaining in March. Meanwhile, major U.S. housing stocks such as Hovnanian and Toll Brothers are down 14-17% last month, retreating from 52-week highs. Investors focus on these shifts ahead of the spring home-selling season and prepare for CNBC's market insights sessions.
Go toTop